Teropavimab

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameTeropavimab
Drug Alias Name3BNC117-LS-J3BNC117-LS3BNC117GS-5423
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionHIV envelope protein gp120 inhibitors
TargetsHIV envelope protein gp120
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaBotswanaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesThe Rockefeller University
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncNational Institute Of Allergy And Infectious Diseases (Niaid)The Rockefeller University
Inactive CompaniesCelldex Therapeutics IncFrontier Biotechnologies IncFrontier Biopharma Company Ltd +[4] 
Active IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A